Physician profile
Michael T Olsen
NPI 1356437891
$2,594.55
in general payments reported to CMS, 2019-2025
32 companies · $766 in 2025
The $766 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $453 · 2021: $113 · 2022: $278 · 2023: $487 · 2024: $286 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $592.19 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $252.20 | 2020-2024 | Mounjaro, Trulicity, Emgality |
| Novo Nordisk INC | $236.76 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $185.95 | 2021-2025 | |
| Amgen INC. | $164.27 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $116.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.28 | 2020-2024 | Jardiance |
| Dexcom, INC. | $102.61 | 2021-2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $96.15 | 2024-2025 | Korlym |
| Abbott Laboratories | $82.80 | 2021-2023 | Freestyle Libre 2 |
| Organon LLC | $63.52 | 2023-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $60.91 | 2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $55.70 | 2020 | |
| Novartis Pharmaceuticals Corporation | $50.09 | 2020-2022 | |
| Amarin Pharma, INC. | $48.05 | 2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $44.39 | 2020 | |
| Idorsia Pharmaceuticals US INC | $44.24 | 2022-2023 | Quviviq |
| Glaxosmithkline, LLC. | $28.79 | 2019-2020 | |
| Astellas Pharma US INC | $28.32 | 2023 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $25.28 | 2020 | |
| Allergan, INC. | $24.45 | 2020 | |
| Axsome Therapeutics, INC. | $19.97 | 2025 | |
| Ferring Pharmaceuticals INC. | $18.95 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.78 | 2025 | |
| Beta Bionics, INC. | $17.25 | 2024 | Ilet Bionic Pancreas |
| Sobi, INC | $16.85 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.14 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $16.12 | 2025 | |
| Xeris Pharmaceuticals, INC. | $15.64 | 2023 | Gvoke Hypopen |
| Ardelyx, INC. | $15.46 | 2025 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $14.60 | 2022 | |
| Tandem Diabetes Care, INC. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.